Patent · US Active

PODXL protein in colorectal cancer

US8999656B2 · kind B2 · utility

143Cited by
1References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 26, 2012
Grant dateApr 7, 2015
Priority date
Expiry dateApr 26, 2032

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/56
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

The present disclosure provides a method for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of PODXL protein in at least part of a sample earlier obtained from the subject, and determining a sample value corresponding to the evaluated amount; b) comparing said sample value from step a) with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to said second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to said first group. Related uses, means and a method of treatment are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.